Two Directors at Boston Scientific Corp sold/sold after exercising options 295,304 shares at between 84.630USD and 85.001USD. The significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by...
Moody's Ratings ("Moody's) affirmed Baxter International Inc.'s ("Baxter") ratings, including its Baa2 senior unsecured ratings and Prime-2 commercial paper rating. The outlook remains stable. The ratings affirmation follows the company's announcement that it plans to sell its Kidney Care business...
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
Regenerative medicine remains an extremely exciting area of healthcare with vast investment potential. In spite of the usual setbacks in valuation and strategy, the sub-sector has pivoted and the market remains innovative and attracts investment capital. Rather than replace entire tissues, which is a complex activity, we believe the immediate future for stem cells is more likely to be in the successful stimulation of the bodies on repair mechanisms. Within regenerative medicine we believe there ...
Moody's Ratings (Moody's) assigned A3 ratings to the new backed senior unsecured notes issued by Medtronic, Inc., a subsidiary of Medtronic plc ("Medtronic"). The notes, including principal and interest payments will be fully guaranteed by Medtronic Global Holdings SCA and the parent, Medtronic plc....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.